Adamis Pharmaceuticals logo
Adamis Pharmaceuticals Schedules Financial Results Conference Call and Business Update
November 19, 2021 15:34 ET | Adamis Pharmaceuticals Corporation
SAN DIEGO, Nov. 19, 2021 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a biopharmaceutical company developing and commercializing specialty products for allergy, opioid...
Adamis Pharmaceuticals logo
Adamis Receives FDA Approval for ZIMHI
October 18, 2021 07:30 ET | Adamis Pharmaceuticals Corporation
SAN DIEGO, Oct. 18, 2021 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (Nasdaq: ADMP) today announced that the U.S. Food and Drug Administration (FDA) has approved Adamis’ ZIMHI™ (naloxone...
Adamis Pharmaceuticals logo
Adamis Announces Appointment of Meera Desai, Ph.D., to Board of Directors
October 04, 2021 07:30 ET | Adamis Pharmaceuticals Corporation
SAN DIEGO, Oct. 04, 2021 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (Nasdaq: ADMP) today announced the appointment of Meera J. Desai, Ph.D., as a new director and member of the company’s...
Adamis Pharmaceuticals logo
Adamis Pharmaceuticals Doses First Patients in Phase 2/3 Clinical Trial for Tempol in the Treatment of COVID-19
September 02, 2021 07:30 ET | Adamis Pharmaceuticals Corporation
SAN DIEGO, Sept. 02, 2021 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (Nasdaq: ADMP) today announced the initiation of patient dosing in the Phase 2/3 clinical trial for Tempol, an oral...
Adamis Pharmaceuticals logo
Adamis Announces Appointment of David C. Benedicto as Chief Financial Officer and Other Events
August 24, 2021 16:05 ET | Adamis Pharmaceuticals Corporation
SAN DIEGO, Aug. 24, 2021 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced that David C. Benedicto, who has been serving as the Company’s Chief Accounting...
Adamis Pharmaceuticals logo
Adamis Pharmaceuticals Announces a Publication with the Human Immune Monitoring Center at Stanford Demonstrating Tempol Significantly Inhibited Multiple Cytokines from COVID-19 Patient’s Cells
August 24, 2021 07:30 ET | Adamis Pharmaceuticals Corporation
Tempol: A potential home treatment for COVID-19 (https://covid19.nih.gov/news-and-stories/tempol-potential-home-treatment-covid-19). Trial to begin shortly. SAN DIEGO, Aug. 24, 2021 (GLOBE...
Adamis Pharmaceuticals logo
Adamis Highlights National Institutes of Health (NIH) Article Entitled, “Tempol: A Potential Home Treatment for COVID-19”
August 19, 2021 07:30 ET | Adamis Pharmaceuticals Corporation
SAN DIEGO, Aug. 19, 2021 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (Nasdaq: ADMP) today highlighted that the NIH has identified Tempol as a potential home treatment for COVID-19...